Phase III top off

Hoping to allow management to focus on Phase III trials and to improve the prospects of finding partners, dievini Hopp BioTech has decided to top off another of its portfolio companies.

Last week, the investor co-led a €53.8 million ($70.5 million) series C round for immatics biotechnologies GmbH, along with new investors MIG Funds and AT Impf. Existing investors Wellington Partners; Grazia Equity; EMBL Ventures; Renaissance PME; Mona Lisa Capital; KfW; National Technology Enterprises; Merifin Capital; Zepta; Beacon Hill; and PB Invest also participated...